{"entity":{"id":"nct04626479","kind":"trial","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Favezelimab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) is a phase 1/2 interventional study registered as NCT04626479 by Merck Sharp & Dohme LLC, with 400 participants enrolled, started 2020-12-16 and due to reach its primary completion in 2026-08-21. Interventions recorded: Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab and Vibostolimab/Pembrolizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04626479","url":"https://clinicaltrials.gov/study/NCT04626479"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","favezelimab","belzutifan","lenvatinib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04626479","phase":"1/2","setting":"A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT04626479","source":"https://clinicaltrials.gov/study/NCT04626479","fetchedAt":"2026-10-07T16:53:23.898Z","studySha256":"2a7c76f8633991a1a0d9051d863d79104b6af8af520dedded9cb2cd314750921","overallStatus":"COMPLETED","lastUpdatePosted":"2026-09-25","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"120 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":393,"enrolmentType":"ACTUAL","siteCount":55,"recruitingSiteCount":0,"countries":["Australia","Canada","Chile","Colombia","France","Hungary","Israel","Netherlands","New Zealand","Poland","South Korea","Spain","United Kingdom","United States"]}],"started":"2020-12-16","startedType":"actual","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04626479/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"},{"id":"favezelimab","kind":"drug","name":"Favezelimab","route":"/drugs/favezelimab/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}